| ²é¿´: 567 | »Ø¸´: 1 | ||
vigorousÌú³æ (СÓÐÃûÆø)
|
[ÇóÖú]
Ò»¶ÎÓ¢ÎÄÕªÒª£¬Ðè·Òë³ÉµÂÎÄ£¬
|
|
ͶÁËһƪµÄµÂ¹úSCIÔÓÖ¾£¬±à¼»ØÐÅ¡° Dear ***£¬ The manuscript cannot start the review process until the following corrections are made to meet the journal's requirements (see Instructions for authors, as well): - please add: German summary with title translation and German keywords - "conclusion for practice" (end of paper) of max. 1.000 signs ÌâÄ¿¼°ÕªÒªÈçÏ The efficacy and safety of rosuvastatin on short-term treating the aged coronary heart disease patients with diabetes mellitus ¡¾Abstract¡¿Background To evaluate the efficacy and safety of statins on short-term treating coronary heart disease patients with diabetes mellitus aged 75 years or older and compare its effects with different doses of atorvastatin simultaneously. Methods A randomized single-blind parallel controlled study was conducted in 116 aged coronary heart disease patients with diabetes mellitus£®The patients were randomly divided into control group and statin treatment groups; receives conventional treatment£¬rosuvastatin 10mg/d£¬atorvastatin 10mg/d or 20mg/d for two weeks£®Results Levels of fasting plasma APN(adiponectin), hs-CRP(high-susceptible C reactive protein), TC£¬TG£¬LDL-C£¬HDL-C£¬ALT(alanine transarninase)£¬AST(aspartate aminotransferase)£¬CR(creatinine) and CPK(creatine phosphokinase) were tested before and after the treatment. Moreover£¬the adverse reactions of patients in statins treatment groups wereobserved£®The results show that the LDL-C level decreased significantly in statin treatment groups(P<0.05)£®Furthermore, the APN and hs-CRP level changed in rosuvastatin group and 20mg/d atorvastatin group£® For four treatment groups£¬the hepatorenal function and CPK level hadn¡¯t significantly changed£®Conclusion It was concluded that rosuvastatin 10mg/d was more effective than atorvastatin 10mg/d and 20mg/d in lipid-lowering and non-lipid-lowering on short term treating the aged coronary heart disease patients with diabetes mellitus based upon the results. However£¬the safety data was similar outcome between them according to a 2-week follow-up study. ¡¾Key Words¡¿ Rosuvastatin£»Atorvastatin£»Coronary Disease£»Diabetes Mellitus£»Treatment Outcome Çë¸ßÊÖ°ïæ£¡»¹ÓУºµÚ¶þ¾ä"conclusion for practice" (end of paper) of max. 1.000 signsÊÇʲôÒâ˼£¿Åª²»Ã÷°× лл£¡ |
» ²ÂÄãϲ»¶
Çó²ÄÁϵ÷¼Á
ÒѾÓÐ7È˻ظ´
Ò»Ö¾Ô¸Ìì´ó²ÄÁÏÓ뻯¹¤£¨085600£©×Ü·Ö338
ÒѾÓÐ3È˻ظ´
085600²ÄÁÏÓ뻯¹¤
ÒѾÓÐ5È˻ظ´
085600²ÄÁÏÓ뻯¹¤µ÷¼Á 324·Ö
ÒѾÓÐ6È˻ظ´
286Çóµ÷¼Á
ÒѾÓÐ9È˻ظ´
½¹ÂÇ
ÒѾÓÐ12È˻ظ´
344Çóµ÷¼Á
ÒѾÓÐ6È˻ظ´
266Çóµ÷¼Á
ÒѾÓÐ9È˻ظ´
»¯Ñ§¹¤³Ì321·ÖÇóµ÷¼Á
ÒѾÓÐ18È˻ظ´
314Çóµ÷¼Á
ÒѾÓÐ8È˻ظ´
vigorous
Ìú³æ (СÓÐÃûÆø)
- Ó¦Öú: 0 (Ó×¶ùÔ°)
- ½ð±Ò: 46.3
- É¢½ð: 356
- ºì»¨: 2
- Ìû×Ó: 92
- ÔÚÏß: 99.7Сʱ
- ³æºÅ: 68737
- ×¢²á: 2005-05-19
- ÐÔ±ð: GG
- רҵ: ´´ÉË
2Â¥2012-01-11 22:50:13













»Ø¸´´ËÂ¥